CD40配体激活增强Docetaxel对乳腺癌细胞增殖的抑制作用

doi:10.3971/j.issn.1000-8578.2010.05.009

CD40配体激活增强Docetaxel对乳腺癌细胞增殖的抑制作用

Inhibitory Effect of Activated CD40Lig with Docetaxel on Breast Cancer Cell Proliferation

摘要

摘要: 目的：探讨rhCD40L联合化疗药Docetaxel对乳腺癌细胞增殖的影响。方法：用MTT法测定CD40⁺的乳腺癌细胞株M231、M435细胞经rhCD40L+Docetaxel处理后的增殖状况；采用碘化丙啶(PI)掺入法测定细胞周期；流式细胞仪检测癌细胞膜分子CD54、CD95及CD95L表达变化。结果：rhCD40L可抑制M231、M435增殖，合用Docetaxel时M231、M435的增殖受到进一步抑制，G₁期细胞数量明显增加( P <0.05)，S期细胞数量下降( P ＜0.05)。CD95表达上调( P <0.05) ，CD54、CD95L表达下调( P <0.05)。结论：rhCD40L可提高Docetaxel对乳腺癌细胞的抗肿瘤效应，其机制可能与rhCD40L将乳腺癌细胞增殖阻滞在G₁期、上调CD95、下调CD54、CD95L表达有关。

Abstract: Objective：To explore the influence of rhCD40L with Docetaxel on proliferation of Breast Cancer Cells．Methods：The proliferation of breast cancer cell lines M231，M435 after treatment with rhCD40L and Docetaxel was analyzed by MTT and cell cycle distribution was detected by FCM with PI staining. The expression of CD54、CD95 and CD95L was also detected by FCM. Results：The proliferation of M231，M435 was inhibited after treatment with rhCD40L( P <0.05). The proliferation of M231，M435 wasfurther inhibited after treatment with rhCD40L and Docetaxel ( P <0.05).The cell number of stage G₁ and S stage was obviously increased，respectively( P <0.05),CD95 was increased obviously( P <0.05), but CD54 and CD95L was significantly decreased( P <0.05)．Conclusion：rhCD40L can enhance the effect of Docetaxel on proliferation inhibition of M231 and M435. It enhances the anti-tumor activity of Docetaxel by inducing cell G₁ arrest，up-regulating CD95 and down-regulating CD54，CD95L.

HTML全文

参考文献(0)

施引文献

资源附件(0)